Use of sacubitril/valsartan early after CABG.

Madina NurzhanovaAisulu MusagaliyevaRaushan ZhakypovaDaniya SenkibayevaAmina Rakisheva

Published in: Open heart (2024)

The early initiation of sacubitril/valsartan in patients after CABG with HFrEF is safe and effective. Adverse events and permanent discontinuation were low. The NT-proBNP concentration reduced significantly with the early in-hospital initiation.

Keyphrases

ejection fraction
end stage renal disease
coronary artery bypass grafting
chronic kidney disease
healthcare
peritoneal dialysis
coronary artery disease
acute coronary syndrome
adverse drug
coronary artery bypass
drug induced